Prestige Consumer Healthcare In found using ticker (PBH) now have 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 72 and 60 calculating the average target price we see 66.4. With the stocks previous close at 58.01 this indicates there is a potential upside of 14.5%. The 50 day MA is 56.79 and the 200 day MA is 57.54. The market capitalisation for the company is $2,929m. You can visit the company’s website by visiting: https://www.prestigebrands.com
The potential market cap would be $3,352m based on the market concensus.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody’s analgesic powders, Boudreaux’s Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden’s cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer’s Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
